Molecular Templates, Inc. (MTEM)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 63.09 Million USD | -43.97% |
| 2022 | 108.62 Million USD | -8.54% |
| 2021 | 118.77 Million USD | 1.97% |
| 2020 | 116.47 Million USD | 71.73% |
| 2019 | 67.82 Million USD | 77.17% |
| 2018 | 38.28 Million USD | 89.0% |
| 2017 | 20.25 Million USD | -16.86% |
| 2016 | 24.36 Million USD | -51.26% |
| 2015 | 49.98 Million USD | 8.73% |
| 2014 | 45.97 Million USD | 19.35% |
| 2013 | 38.51 Million USD | 48.92% |
| 2012 | 25.86 Million USD | -14.06% |
| 2011 | 30.09 Million USD | 25.89% |
| 2010 | 23.9 Million USD | 12.12% |
| 2009 | 21.32 Million USD | 5.7% |
| 2008 | 20.17 Million USD | -40.29% |
| 2007 | 33.78 Million USD | -44.36% |
| 2006 | 60.72 Million USD | 28.57% |
| 2005 | 47.22 Million USD | 297.22% |
| 2004 | -23.94 Million USD | -388.19% |
| 2003 | 8.3 Million USD | 234.37% |
| 2002 | 2.48 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 9.98 Million USD | -10.09% |
| 2024 Q2 | 7.79 Million USD | -15.02% |
| 2023 FY | 60.86 Million USD | -43.97% |
| 2023 Q3 | 11.93 Million USD | -35.04% |
| 2023 Q1 | 21.84 Million USD | -7.72% |
| 2023 Q2 | 18.37 Million USD | -15.9% |
| 2023 Q4 | 11.1 Million USD | -6.94% |
| 2022 FY | 108.62 Million USD | -8.54% |
| 2022 Q1 | 29.11 Million USD | 6.79% |
| 2022 Q2 | 28.25 Million USD | -2.96% |
| 2022 Q4 | 23.67 Million USD | -15.18% |
| 2022 Q3 | 27.9 Million USD | -1.24% |
| 2021 FY | 118.77 Million USD | 1.97% |
| 2021 Q2 | 30.04 Million USD | 1.69% |
| 2021 Q3 | 31.9 Million USD | 6.19% |
| 2021 Q4 | 27.26 Million USD | -14.55% |
| 2021 Q1 | 29.54 Million USD | 0.46% |
| 2020 FY | 116.47 Million USD | 71.73% |
| 2020 Q1 | 23.93 Million USD | 13.49% |
| 2020 Q2 | 35.95 Million USD | 50.22% |
| 2020 Q3 | 27.16 Million USD | -24.44% |
| 2020 Q4 | 29.41 Million USD | 8.26% |
| 2019 Q1 | 12.79 Million USD | 17.68% |
| 2019 Q3 | 19.32 Million USD | 32.27% |
| 2019 Q4 | 21.09 Million USD | 9.13% |
| 2019 FY | 67.82 Million USD | 77.17% |
| 2019 Q2 | 14.61 Million USD | 14.21% |
| 2018 Q3 | 7.1 Million USD | -35.14% |
| 2018 FY | 38.28 Million USD | 89.0% |
| 2018 Q4 | 10.87 Million USD | 52.98% |
| 2018 Q1 | 9.34 Million USD | 26.98% |
| 2018 Q2 | 10.95 Million USD | 17.24% |
| 2017 Q2 | 2.8 Million USD | -36.93% |
| 2017 Q1 | 4.44 Million USD | -10.48% |
| 2017 FY | 20.25 Million USD | -16.86% |
| 2017 Q4 | 7.36 Million USD | 12.92% |
| 2017 Q3 | 6.51 Million USD | 132.62% |
| 2016 Q1 | 8.25 Million USD | -39.38% |
| 2016 Q4 | 4.96 Million USD | -5.23% |
| 2016 FY | 24.36 Million USD | -51.26% |
| 2016 Q3 | 5.23 Million USD | -11.36% |
| 2016 Q2 | 5.9 Million USD | -28.42% |
| 2015 Q2 | 12.62 Million USD | -5.08% |
| 2015 FY | 49.98 Million USD | 8.73% |
| 2015 Q4 | 13.61 Million USD | 30.27% |
| 2015 Q3 | 10.45 Million USD | -17.18% |
| 2015 Q1 | 13.29 Million USD | 18.38% |
| 2014 Q4 | 11.23 Million USD | -0.72% |
| 2014 FY | 45.97 Million USD | 19.35% |
| 2014 Q1 | 12.28 Million USD | 11.84% |
| 2014 Q2 | 11.14 Million USD | -9.33% |
| 2014 Q3 | 11.31 Million USD | 1.54% |
| 2013 FY | 38.51 Million USD | 48.92% |
| 2013 Q1 | 8.98 Million USD | 12.09% |
| 2013 Q2 | 10.14 Million USD | 12.98% |
| 2013 Q3 | 8.4 Million USD | -17.22% |
| 2013 Q4 | 10.98 Million USD | 30.77% |
| 2012 Q1 | 7.39 Million USD | -9.4% |
| 2012 Q3 | 5.78 Million USD | 23.58% |
| 2012 FY | 25.86 Million USD | -14.06% |
| 2012 Q2 | 4.67 Million USD | -36.75% |
| 2012 Q4 | 8.01 Million USD | 38.65% |
| 2011 FY | 30.09 Million USD | 25.89% |
| 2011 Q4 | 8.16 Million USD | 4.79% |
| 2011 Q1 | 7.39 Million USD | 20.76% |
| 2011 Q3 | 7.78 Million USD | 15.34% |
| 2011 Q2 | 6.75 Million USD | -8.67% |
| 2010 Q4 | 6.12 Million USD | 0.87% |
| 2010 Q1 | 5.75 Million USD | 4.85% |
| 2010 FY | 23.9 Million USD | 12.12% |
| 2010 Q2 | 5.95 Million USD | 3.53% |
| 2010 Q3 | 6.07 Million USD | 1.86% |
| 2009 FY | 21.32 Million USD | 5.7% |
| 2009 Q4 | 5.49 Million USD | 5.41% |
| 2009 Q3 | 5.2 Million USD | -4.53% |
| 2009 Q2 | 5.45 Million USD | 5.49% |
| 2009 Q1 | 5.17 Million USD | -1.2% |
| 2008 FY | 20.17 Million USD | -40.29% |
| 2008 Q3 | 5.01 Million USD | 235.79% |
| 2008 Q4 | 5.23 Million USD | 4.35% |
| 2008 Q2 | -3.69 Million USD | -167.02% |
| 2008 Q1 | 5.51 Million USD | -31.43% |
| 2007 Q3 | 7.3 Million USD | 194.4% |
| 2007 Q4 | 8.03 Million USD | 10.08% |
| 2007 FY | 33.78 Million USD | -44.36% |
| 2007 Q1 | 9.99 Million USD | -6.78% |
| 2007 Q2 | -7.73 Million USD | -177.44% |
| 2006 FY | 60.72 Million USD | 28.57% |
| 2006 Q1 | 15.25 Million USD | -7.42% |
| 2006 Q4 | 10.71 Million USD | -40.22% |
| 2006 Q3 | 17.92 Million USD | 6.54% |
| 2006 Q2 | 16.82 Million USD | 10.33% |
| 2005 Q4 | 16.47 Million USD | 33.66% |
| 2005 Q1 | 7.81 Million USD | 119.57% |
| 2005 Q2 | 10.61 Million USD | 35.79% |
| 2005 FY | 47.22 Million USD | 297.22% |
| 2005 Q3 | 12.32 Million USD | 16.13% |
| 2004 Q4 | -39.93 Million USD | -849.25% |
| 2004 FY | -23.94 Million USD | -388.19% |
| 2004 Q3 | 5.33 Million USD | 0.0% |
| 2003 FY | 8.3 Million USD | 234.37% |
| 2002 FY | 2.48 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| America Great Health | 661.23 Thousand USD | -9441.432% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -580.74% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -110.352% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 6.04% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -298.226% |
| Better Therapeutics, Inc. | 38.26 Million USD | -64.892% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -55.057% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -409.097% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -86.417% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -83.303% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 41.833% |
| Evolutionary Genomics, Inc. | 992.8 Thousand USD | -6254.797% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -93.596% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -34.376% |
| Innovation1 Biotech Inc. | 1.21 Million USD | -5094.009% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -216.415% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | -352.863% |
| NexImmune, Inc. | 28.16 Million USD | -123.985% |
| Orgenesis Inc. | 45.75 Million USD | -37.883% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -145.998% |
| Point of Care Nano-Technology, Inc. | 73.41 Thousand USD | -85836.308% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -290.771% |
| Scopus BioPharma Inc. | 11.71 Million USD | -438.555% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 84.367% |
| Statera Biopharma, Inc. | 28.82 Million USD | -118.842% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -233.303% |
| Trevena, Inc. | 38.41 Million USD | -64.244% |
| Vaxxinity, Inc. | 56.05 Million USD | -12.56% |
| Vaccinex, Inc. | 23.45 Million USD | -168.987% |
| Vicapsys Life Sciences, Inc. | 1.04 Million USD | -5926.01% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -24.457% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -767.275% |